Healthcare
Angiex, Inc.
Recorded December 10, 2024
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ to make cancer less lethal.
The company’s AI-powered drug development program has the potential to treat multiple CNS diseases and impact millions of lives.
A clinical-stage biotechnology company pioneering an Intestinal Microbiota Transplant (IMT) platform designed to transform patients’ lives.
Deep sea nodule collection provides higher quality critical minerals with significantly lower environmental impact than traditional mining.
Vericatch is helping the global commercial fishing industry become more sustainable, efficient, accountable, and profitable.
First-in-industry devices to optimize cancer therapies and address infectious disease disorders that are not treatable with drugs
The world-class antibody engineers at OncoOne are creating monoclonal antibodies to treat diseases with exacting specificity and precision
Direct Biologics is a clinical-stage biotech innovator that is harnessing signaling molecules to reduce overactive inflammatory response
D-ID’s AI-powered digital video platform seamlessly transforms images, text, videos, audio, and voice into highly engaging Digital People
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
Element Fleet has a developed a new securitized trust that has the potential to deliver significant tax advantages
The company’s AI-powered drug development program has the potential to treat multiple CNS diseases and impact millions of lives.